Tresperimus: a new agent for transplant tolerance induction

Bibliography

• HARIHARAN S, JOHNSON CP, BRESNAHAN BA et al.: Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl. J Med. (2000) 342:605–612.
   PubMed Web of Science ®Google Scholar
• PARIKH C & ELLISON DH: Improved graft survival after renal transplantation in the United States, 1988 to 1996 [letter]. N Engl..). Med. (2000) 342:1837;Discussion 1838.
   Google Scholar
• MATZINGER P: Graft tolerance: a duel of two signals. Nat. Med. (1999) 5:616–617.
   PubMed Web of Science ®Google Scholar
• •A concise review of the role of CD40 in B-and T-cell immunity.
   Google Scholar
• VENDETTI S, CHAT JG, DYSON J etal.: Anergic T cells inhibit the antigen-presenting function of dendritic cells. Immunol. (2000) 165:1175–1181.
   Google Scholar
• ••This is one of the best articles in describingthe characteristics of inhibitory CD4 cells.
   Google Scholar
• UMEDA Y, MORIGUCHI M, KURODA H et al: Synthesis and antitumor activity of spergualin analogues. II. Chemical modification of the spermidine moiety. j Antibiot. (Tokyo) (1987) 40:1303–1315.
   PubMed Web of Science ®Google Scholar
• TAKEUCHI T, IINUMA H, KUNIMOTO S et al: A new antitumor antibiotic, spergualin: isolation and antitumor activity. Antibiot. (Tokyo) (1981) 34:1619–1621.
   PubMed Web of Science ®Google Scholar
• UMEDA Y, MORIGUCHI M, KURODA H et al: Synthesis and antitumor activity of spergualin analogues. I. Chemical modification of 7-guanidino-3-hydroxyacyl moiety. j Antibiot. (Tokyo) (1985) 38:886–898.
   PubMed Web of Science ®Google Scholar
• TAMURA K, NIITANI H, OGURO M et al.: Phase I study of NKT-01. Cancer Chemother. Pharmacy]. (1995) 36:189–194.
   PubMed Web of Science ®Google Scholar
• •This paper gives a good profile of the toxicity of DSG, which is very similar to that seen with tresperimus.
   Google Scholar
• NEMOTO K, HAYASHI M, ABE F et al: Suppression of humoral immunity in mice by spergualin. Transplant Proc. (1987) 19:4638–4640.
   PubMed Web of Science ®Google Scholar
• OCHIAI T, HORI S, NAKAJIMA K etal.: Prolongation of rat heart allograft survival by 15-deoxyspergualin.j Antibiot. (Tokyo) (1987) 40:249–250.
   Google Scholar
• DUTARTRE P, ANNAT J & DERREPAS P: LF 08-0299 induces tolerance after short-term treatment in a fully major histocompatibility mismatched rat cardiac allograft model. Transplant Proc. (1995) 27:440–442.
   PubMed Web of Science ®Google Scholar
• •This paper describes the effect of different doses, durations and routes of administration of tresperimus in a cardiac transplant model. It also demonstrates tolerance induction by tresperimus.
   Google Scholar
• Tresperimus. LF 080299. Drugs R&D (1999) 1:110–111.
   PubMedGoogle Scholar
• ANDOINS C, DE FORNEL D, ANNAT J, DUTARTRE P: Tolerance in a rat cardiac allograft model after short-term treatment with LF 08-0299. Absence of clonal deletion and evidence of CD4+ suppressor cells. Transplantation (1996) 62:1543–1549.
   Google Scholar
• ••In a follow-up to earlier work, this studyshows that induction of CD4 suppressor cells is the mechanism by which long term tolerance is achieved.
   Google Scholar
• ZIMMERMANN R: The role of molecular chaperones in protein transport into the mammalian endoplasmic reticulum. Biol. Chem. (1998) 379:275–282.
   PubMed Web of Science ®Google Scholar
• BINDER RJ, BLACHERE NE & SRI VASTAVA PK: Heat shock protein-chaperoned peptides but not free peptides introduced into the cytosol are presented efficiently by major histocompatibility complex I molecules.j Biol. Chem. (2001) 276:17163–17171.
   PubMed Web of Science ®Google Scholar
• REIMANN J, SCHIRMBECK R: Alternative pathways for processing exogenous and endogenous antigens that can generate peptides for MHC class I-restricted presentation. Immunol Rev (1999) 172:131–152.
   PubMed Web of Science ®Google Scholar
• KOMESLI S, DUMAS C & DUTARTRE P: Analysis of in vivo immunosuppressive and in vitro interaction with constitutive heat shock protein 70 activity of LF08-0299 (Tresperimus) and analogues. Int. Immunopharmacology (1999) 21:349–358.
   PubMed Web of Science ®Google Scholar
• •This paper updates the role of Hsc70 interaction as the molecular basis of immunosuppression with tresperimus.
   Google Scholar
• FERREIRA V, SIDENIUS N, TARANTINO N et al: In vivo inhibition of NF-1c13 in T-lineage cells leads to a dramatic decrease in cell proliferation and cytokine production and to increased cell apoptosis in response to mitogenic stimuli, but not to abnormal thymopoiesis.j. Immunol (1999) 162:6442–6450.
   PubMed Web of Science ®Google Scholar
• TEPPER MA, NADLER SG, ESSELSTYN JM, STERBENZ KG: Deoxyspergualin inhibits kappa light chain expression in 70Z/ 3 pre-B cells by blocking lipopolysaccharide-induced NF-icB activation. j Immuriol (1995) 155:2427–2436.
   Google Scholar
• WU L, D'AMICO A, WINKEL KD etal.: RelB is essential for the development of myeloid-related CD8a- dendritic cells but not of lymphoid-related CD8a+ dendritic cells. Immunity (1998) 9:839–847.
   Google Scholar
• SMILEY ST, CSIZMADIA V, GAO W, TURKA LA, HANCOCK WW: Differential effects of cyclosporine A, methylprednisolone, mycophenolate, and rapamycin on CD154 induction and requirement for NFkappaB: implications for tolerance induction. Transplantation (2000) 70:415–419.
   PubMed Web of Science ®Google Scholar
• HINZ M, LOSER P, MATHAS S et al: Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells. Blood (2001) 97:2798–2807.
   PubMed Web of Science ®Google Scholar
• ••NK-tc13 has been impicated in manypathways. This paper helps to narrow down the role of this nuclear protein in cell signalling.
   Google Scholar
• IMAMURA M, HAN M, HASHINO S et al.: In vivo effects of the immuno-suppressant 15-deoxyspergualin on hematopoiesis in murine allogeneic bone marrow chimeras. Its thrombopoietic activity and reversal of adverse effects with granulocyte colony-stimulating factor and/ or erythropoietin. Transplantation (1994) 58:214–223.
   Google Scholar
• DI MARCO R, ZACCONE E MAGRO G et al.: Synergistic effect of deoxyspergualin (DSP) and cyclosporin A (CsA) in the prevention of spontaneous autoimmune diabetes in BB rats. Clin Exp. Immuriol (1996) 105:338–343.
   Google Scholar
• KIRK AD, BURKLY LC, BATTY DS et al.: Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat. Med. (1999) 5:686–693.
   PubMed Web of Science ®Google Scholar
• ••This paper shows that tolerance inductionis successful in large animal models of organ transplantation, paying the way for clinical use of these agents.
   Google Scholar
• LI Y, LI XC, ZHENG XX et al: Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat. Med. (1999) 5:1298–1302.
   PubMed Web of Science ®Google Scholar
• ••An important paper in defining theinteraction of standard immuno-suppressive agents with tolerance inducing drugs.
   Google Scholar
• YUH DD, MORRIS RE: The immunopharmacology of immunosuppression by 1 5-deoxyspergualin. Transplantation (1993) 55:578–591.
   PubMed Web of Science ®Google Scholar
• CLAUD E PAD OVANI E GUICHARD JP ARTUR Y, LAINE R: Involvement of semicarbazide-sensitive amine oxidase in tresperimus metabolism in human and in rat. Drug Metab. Dispos. (2001) 29:735–741.
   PubMed Web of Science ®Google Scholar
• POWLES R, KULKARNI S, SIROHI B et al.: PhaseI/II evaluation of intravenous Tresperimus (LF 08-0299) and methylprednisolone as first line therapy for acute graft versus host disease. Blood (1999) 94:4707a.
   Google Scholar
• •This article is one of the few published reports of tresperimus use in patients.
   Google Scholar
• AMEMIYA H, SUZUKI S, OTA K et al: A novel rescue drug, 1 5-deoxyspergualin. First clinical trials for recurrent graft rejection in renal recipients. Transplantation (1990) 49:337–343.
   Google Scholar
• AMEMIYA H, SUZUKI S, OTA K et al: Multicentre clinical trial of antirejection pulse therapy with deoxyspergualin in kidney transplant patients. Int. Pharmacol Res. (1991) 11:175–182.
   PubMed Web of Science ®Google Scholar
• MATAS AJ, GORES PF, KELLEY SL et al: Pilot evaluation of 15-deoxyspergualin for refractory acute renal transplant rejection. OM. Transplant. (1994) 8:116–119.
   Web of Science ®Google Scholar
• KASAI M, HIGA T, NAOHARA T et al.:15-Deoxyspergualin controls cyclosporin- and steroid-resistant intestinal acute graft- versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant (1994) 14:315–317.
   PubMed Web of Science ®Google Scholar
• GORES PF: Deoxyspergualin: clinical experience. Transplant Proc. (1996) 28:871–872.
   PubMed Web of Science ®Google Scholar
• HAVLIN KA, KUHN JG, KOELLER J etal.: Deoxyspergualin: Phase I clinical, immunologic and pharmacokinetic study. Anti-Cancer Drugs (1995) 6:229–236.
   Google Scholar
• LEBRETON L, JOST E, CARBONI B et al:Structure-immunosuppressive activity relationships of new analogues of 15-deoxyspergualin. 2. Structural modifications of the spermidine moiety. j Med. Chem. (1999) 42:4749–4763.
   Google Scholar